R. Scotland

Granulocyte‐macrophage–colony‐stimulating factor added to a multipeptide vaccine for resected Stage II melanoma

V. Sondak, S. Groshen, J. Weber, 2003, Cancer.

Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs.

A. Korman, J. Weber, R. Scotland, 2007, International immunology.

A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma.

S. Groshen, J. Weber, S. Woulfe, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Alum with Interleukin-12 Augments Immunity to a Melanoma Peptide Vaccine: Correlation with Time to Relapse in Patients with Resected High-Risk Disease

W. Ye, S. Groshen, O. Hamid, 2007, Clinical Cancer Research.

Characterization of Long-Term Effector-Memory T-Cell Responses in Patients with Resected High-Risk Melanoma Receiving a Melanoma Peptide Vaccine

J. Weber, J. Delto, R. Scotland, 2004, Journal of immunotherapy.

Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma.

S. Groshen, J. Weber, T. Keler, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of extended dose anti-CTLA-4 antibody ipilimumab (formerly MDX-010) with a multi-peptide vaccine for resected stages IIIC and IV melanoma.

S. Targan, J. Weber, M. Yellin, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.